Sesen Bio, Inc. SESN · Stock Open Sesen Bio, Inc. in new tab
Sesen Bio, Inc. Analysis (SESN)
Is Sesen Bio, Inc. a good investment? Sesen Bio, Inc. (SESN) is currently trading at 0.6288 USD.
For income investors, Sesen Bio, Inc. pays a dividend yield of 57.25%.
Investor FAQ
Does Sesen Bio, Inc. pay a dividend?
Yes, it pays an annual dividend of 0.36 USD (57.25% yield).
What asset class is Sesen Bio, Inc.?
Sesen Bio, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
| Year | Total Dividends |
|---|---|
| ▸2023 |
0.02 USD
|
| March 6, 2023 | 0.0180 |
| Split Date | Split Ratio to 1 |
|---|---|
| March 8, 2023 | 0.050000 |
Community Discussion